Sign In
Buy CLLS
$2.75
-0.100 (-3.51%)
At Close: Jul 31, 2026
Cellectis Announces the Appointment of Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D., to its Board of Directors
08:36pm, Tuesday, 28'th Jun 2022 GlobeNewswire Inc.
NEW YORK, June 28, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform t
Cellectis annonce les nominations d'Axel-Sven Malkomes et de Donald A Bergstrom, M.D., Ph.D. à son conseil d'administration
08:36pm, Tuesday, 28'th Jun 2022 GlobeNewswire Inc.
NEW YORK, 28 juin 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de géno
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 28, 2022
08:08pm, Tuesday, 28'th Jun 2022 GlobeNewswire Inc.
NEW YORK, June 28, 2022 (GLOBE NEWSWIRE) -- Cellectis S.A. held its Annual Shareholders’ General Meeting (Euronext Growth: ALCLS – Nasdaq: CLLS) on June 28, 2022 at its head office in Paris, Fra
Résultats de l’Assemblée Générale Mixte des Actionnaires de Cellectis S.A. du 28 juin 2022
08:08pm, Tuesday, 28'th Jun 2022 GlobeNewswire Inc.
NEW YORK, 28 juin 2022 (GLOBE NEWSWIRE) -- L’Assemblée Générale à caractère mixte de Cellectis (Euronext Growth : ALCLS – Nasdaq : CLLS) s’est tenue le mardi 28 juin 2022 à Paris, au si�
Seer, Inc. (SEER) Stock Jumps 12.9%: Will It Continue to Soar?
01:39pm, Monday, 27'th Jun 2022 Zacks Investment Research
Seer, Inc. (SEER) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase
Iovance (IOVA) Pipeline Aids Growth Amid Lack of Marketed Drugs
02:48pm, Wednesday, 22'nd Jun 2022 Zacks Investment Research
Iovance (IOVA) is progressing well with the clinical development of its pipeline candidates. It expects to file a BLA with the FDA, seeking approval for its lead candidate to treat metastatic melanoma
Monthly information on share capital and company voting rights
08:30pm, Wednesday, 08'th Jun 2022 GlobeNewswire Inc.
(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
08:30pm, Wednesday, 08'th Jun 2022 GlobeNewswire Inc.
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers)
Cellectis’ Annual Shareholders’ General Meeting to be Held on June 28, 2022
08:35pm, Monday, 23'rd May 2022 GlobeNewswire Inc.
NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving
L’Assemblée Générale Mixte de Cellectis se tiendra le 28 juin 2022
08:35pm, Monday, 23'rd May 2022 GlobeNewswire Inc.
NEW YORK, 23 mai 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth : ALCLS ; Nasdaq : CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d’édition de
Why Cellectis' Shares Rose 22.7% This Week
11:35pm, Friday, 20'th May 2022 The Motley Fool
The company bucked the recent downward trend for biotech companies.
Why Cellectis' Shares Rose 22.7% This Week
07:35pm, Friday, 20'th May 2022
The company bucked the recent downward trend for biotech companies.
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2022
02:13pm, Wednesday, 18'th May 2022 Benzinga
Upgrades
According to William Blair, the prior rating for On Holding AG (NYSE:ONON) was changed from Sell to Hold. At the moment, the stock has a 52-week-high of $55.87 and a 52-week-low of $16.38. O
Cellectis présente des données de recherche d’une nouvelle cellule CAR T universelle au congrès annuel de l’ASGCT
12:15pm, Monday, 16'th May 2022 GlobeNewswire Inc.
NEW YORK, 16 mai 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génom
Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGCT
12:15pm, Monday, 16'th May 2022 GlobeNewswire Inc.
NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to
